FORUM Pharmaceuticals Inc., a biopharmaceutical company singularly focused on the development and delivery of innovative medicines to treat serious brain diseases, has relocated its corporate headquarters to a 112,500 s/f, facility located at 225 Second Ave. The move consolidates FORUM's operations into a single centralized location that houses corporate offices, clinical development and research laboratories. Prior to the move, FORUM conducted business from two locations in Watertown, Mass. and Brighton, Mass. The company also maintains a small European office in The Netherlands.
The property at 225 Second Ave. is owned and operated by an affiliate of Alexandria Real Estate Equities, Inc. Robert Richards, partner, Transwestern | RBJ represented FORUM in the transaction. Building ownership was represented internally by Thomas Andrews, executive vice president, and Dan Cordeau, vice president of leasing.
"We are excited to be located under one roof in Waltham, as it facilitates daily interaction of our development and commercial teams with research scientists to drive continued innovation in FORUM's focused product pipeline that targets serious brain diseases such as schizophrenia, Alzheimer's disease and frontotemporal dementia," said Deborah Dunsire, M.D., president and CEO of FORUM Pharmaceuticals. "With our lead product candidate, encenicline, in two large Phase 3 clinical trials for schizophrenia and Alzheimer's disease, our genetically-targeted therapy, FRM-0334, in a Phase 2 trial for a genetic variant of frontotemporal dementia, as well as our robust drug discovery efforts, we need to plan for FORUM's future growth as we bring new medicines to patients. This state-of-the-art, custom designed facility is a critical next step in our advancement. We look forward to being an active and productive member of the Waltham business community."